Abstract
Fluconazole is an effective bis-triazole oral antifungal agent indicated for the treatment of systemic and superficial candidiasis. The clinical pharmacokinetics and relative bioavailability (bioequivalence) of a single dose of new generic formula (capsule) containing 150 mg fluconazole as a test product was compared against the brand product Diflcan® 150 mg capsule, Pfizer, as a reference product. Both products were administered to 28 healthy Arabic adult males applying fasting, a two-sequence,
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal Of Advanced Pharmacy Education And Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
